NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News  » Business » Pfizer to pay $55 million to settle Protonix case

Pfizer to pay $55 million to settle Protonix case

Last updated on: December 13, 2012 09:36 IST

Pfizer to pay $55 million to settle Protonix case

Pfizer Inc will pay $55 million plus interest to settle charges that Wyeth promoted its acid reflux drug Protonix for unapproved uses and made unproven claims about the medicine, the US Department of Justice said on Wednesday.

The infractions took place between February 2000 and June 2001, long before the world's largest drugmaker acquired Wyeth in 2009 for $68 billion. Protonix, which belongs to a class of widely used medicines called proton pump inhibitors (PPI), has since gone off patent and is available in cheap generic versions as pantoprazole.

Protonix was approved by the US Food and Drug Administration for short-term treatment of erosive esophagitis -a condition related to gastro-esophageal reflux disease, or GERD, that can only be diagnosed via endoscopy.

The Justice Department accused Wyeth of training its sales force to promote Protonix for all forms of GERD, which is far more common and likely to lead to significantly higher sales.

In addition, Wyeth allegedly promoted Protonix as the "best PPI for nighttime heartburn" even though there was never any clinical evidence that it was more effective than any other PPI, such as AstraZeneca's Nexium, for that use, the Justice Dept said.

"Wyeth tried to cheat the system by obtaining a limited FDA approval for Protonix, fully intending to promote this drug for additional, unapproved uses," US Attorney Carmen Ortiz said in a statement.

© Copyright 2018 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.